Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza
about
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypesViral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-AntagonistsInduction of innate immunity and its perturbation by influenza virusesInfluenza virus hemagglutinin stalk-based antibodies and vaccinesAttenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine ApproachVaccines: the Fourth CenturyReverse Genetics Approaches for the Development of Influenza VaccinesInfluenza A virus attenuation by codon deoptimization of the NS gene for vaccine developmentChanging risk awareness and personal protection measures for low to high pathogenic avian influenza in live-poultry markets in Taiwan, 2007 to 2012A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferonAvian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetA replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in miceMutations to PB2 and NP proteins of an avian influenza virus combine to confer efficient growth in primary human respiratory cells.A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Current and emerging cell culture manufacturing technologies for influenza vaccines.A paradigm shift in vaccine production for pandemic influenza.Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.H7N9 influenza virus neutralizing antibodies that possess few somatic mutationsSeveral hemagglutinins of same serotype for induction of broad immunity against influenza A virus antigenic drift variants: WO2008048984.NS-based live attenuated H1N1 pandemic vaccines protect mice and ferretsPandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus.Programming the magnitude and persistence of antibody responses with innate immunity.A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains.Differential contribution of PB1-F2 to the virulence of highly pathogenic H5N1 influenza A virus in mammalian and avian species.New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.New technologies for influenza vaccines.Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice.Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.H5N1 pathogenesis studies in mammalian models.Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines.Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses.The impact of matching vaccine strains and post-SARS public health efforts on reducing influenza-associated mortality among the elderly.Innate immune evasion strategies of influenza virusesThe HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets.A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.The C-Terminal Effector Domain of Non-Structural Protein 1 of Influenza A Virus Blocks IFN-β Production by Targeting TNF Receptor-Associated Factor 3Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.
P2860
Q24614628-D0D31A51-18C6-406A-A2D8-F15A183199EDQ26745547-F4D844AE-860A-4C9F-9D1E-0F0D08F90C43Q26800014-DC084F8F-F6C8-4B8D-B847-731B385B6214Q27001190-577B6913-424D-4733-9FF5-A5769679461AQ27316846-B7BB909B-6FBD-435D-BA54-A16682708191Q27490454-7AC6F935-34F8-4EB5-A05D-CDE88AE6A092Q28076140-AC87B57E-637D-4115-B064-74A2AB65CA67Q28395006-F6FAB101-D94C-4629-AF6D-C73E16D85546Q28397058-340ADC7B-AAAE-4AAF-BE26-B7CB50C9982DQ28483298-402EAC25-0C1F-41B2-A86F-747AFF018D04Q30227194-FBE334B0-C97B-42CB-A693-E650C3B9C0E1Q30357094-3EA10B2A-5459-45F2-A082-6D5926A2F6DCQ30366669-1CD49AED-583F-4110-8A00-A9A46D7E06B7Q30370147-1C0F1A43-D85C-4E1B-B79C-E520007CC90FQ30373128-3906D7A2-5F81-44E2-8538-AA1AC2571FFEQ30377766-61972536-C58A-4D7C-B7A6-0F02CAB96C83Q30378132-6628AFA5-E386-481D-9128-8274DCAA5BFBQ30382576-62ED09AB-D487-48D3-AD16-FEA03ED9BED5Q30385271-DE541818-6E42-4BC7-827B-9FC86C109E01Q30385356-A7FA52FA-3C9C-422F-B22B-160A959F50B7Q30385956-7F5AD2E5-ED16-49A4-A158-675B73AF73F4Q30394706-151D3BA5-4A56-45EA-AD01-807992C0C147Q30395264-D960FAFC-25C6-4497-B248-EDEBA37B4B60Q30400144-3CD7C0C5-2A28-44B2-957D-D67B95DC5085Q30402334-AC0193F9-6D78-4337-AFED-E14C6FEADA1EQ30406151-9D3F8338-BF3A-4A1E-8768-7D32AD92F03DQ30407424-8B2229C1-785F-4EB5-A15C-2138211C01EBQ30411859-54339064-3B67-4144-A941-795902D7AE1FQ30419085-AE285982-A77B-4CD7-B080-4919C70291D5Q30423481-A7C8E94E-77D2-43F9-B006-ECF269C30ECCQ30427806-19C7ED02-276F-460E-A348-703BBF296FD8Q30474419-58E07529-4410-4AD5-AB38-4F579D699765Q30540603-A7AB6D3E-D3F5-42A0-86DD-6D8944C35091Q33490614-0BB840E4-B926-4BAE-A449-3A56B98D46CCQ33622358-228404B7-9135-4C7C-9CF4-B4E38A2D25AEQ33646273-2B7E89DA-DB50-49FA-A8D2-DF0EFF769115Q33700611-8A41C0C4-A8CD-4093-A5C4-3524D16F2EA1Q33815195-FAF6689E-DA4F-4539-845A-44C0F3D1E0AFQ33863827-FCD73AF1-1979-4579-A005-3303AFCF539EQ33883224-A4AE3CD2-42F2-4227-94C7-1AD32595B88F
P2860
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Live attenuated influenza viru ...... hly pathogenic avian influenza
@ast
Live attenuated influenza viru ...... hly pathogenic avian influenza
@en
Live attenuated influenza viru ...... hly pathogenic avian influenza
@nl
type
label
Live attenuated influenza viru ...... hly pathogenic avian influenza
@ast
Live attenuated influenza viru ...... hly pathogenic avian influenza
@en
Live attenuated influenza viru ...... hly pathogenic avian influenza
@nl
prefLabel
Live attenuated influenza viru ...... hly pathogenic avian influenza
@ast
Live attenuated influenza viru ...... hly pathogenic avian influenza
@en
Live attenuated influenza viru ...... hly pathogenic avian influenza
@nl
P2093
P2860
P50
P356
P1433
P1476
Live attenuated influenza viru ...... hly pathogenic avian influenza
@en
P2093
Anice C Lowen
John Steel
Lindomar Pena
Matthew Angel
P2860
P304
P356
10.1128/JVI.01920-08
P407
P577
2009-02-01T00:00:00Z